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Molecular changes in premenopausal oestrogen receptor-
positive primary breast cancer in Vietnamese women after
oophorectomy
Ben P. Haynes1, Ophira Ginsburg2,3, Qiong Gao4, Elizabeth Folkerd1, Maria Afentakis1, Le Hong Quang5, Pham Thi Han6,
Pham Hong Khoa5, Nguyen Van Dinh5, Ta Van To6, Mark Clemons7, Ian E. Smith8 and Mitch Dowsett1,4
For premenopausal women with primary ER + breast cancer, oophorectomy (OvX) is an evidence-based cost-effective option and is
standard treatment in many countries. However, there is virtually no data describing the effects of OvX on breast tumour biology.
We therefore, characterised the endocrine and genome-wide transcriptional impact of OvX in 56 premenopausal women with ER +
breast cancer for 2 weeks prior to mastectomy. Plasma estradiol concentrations decreased from 406 ± 41 to 20.7 ± 2.6 pmol/l (mean
± sem) 24 h after OvX, and to 8.1 ± 0.8 pmol/l 2 weeks later at mastectomy. Ki67 decreased in 33/36 (91.7%) tumours. The
expression of 655 genes changed signiﬁcantly (FDR < 1%) with an absolute mean fold-change (FC)≥ 1.25 (257 up, 398 down).
Archetypal oestrogen-regulated genes (TFF1, GREB1, PGR and PDZK1) showed large decreases in expression (FC = 0.20–0.69; p < 1e-
6-1e-7). Proliferation-associated genes (e.g. TOP2A, AURKA and UBE2C) were also strongly downregulated (FC = 0.38–0.56; p < 1e-7)
along with putative progesterone-regulated genes (e.g. FKBP4, MYB; FC = 0.64–0.68; p < 1e-4-1e-7). The gene expression changes
did not differ according to HER2 status and correlated strongly with the changes reported previously after aromatase inhibitor (AI)
treatment in postmenopausal women (rho = 0.55, p < 1e-04). However, after OvX the mean FC was signiﬁcantly higher compared to
AI (p < 1e-04). In conclusion, changes in tumoural gene expression after OvX were largely similar, but of a greater magnitude to
those observed after AI in postmenopausal patients; however, OvX appeared to have a greater effect on progesterone-regulated
genes than AI.
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INTRODUCTION
The use of surgical OvX was ﬁrst described by Beatson as an
endocrine treatment for breast cancer over 120 years ago.1 OvX
with or without tamoxifen is an evidence-based cost-effective
option for ﬁrst-line adjuvant treatment of premenopausal women
with ER + breast cancer after mastectomy who decline or
otherwise lack access to chemotherapy.2–4 The majority of women
with breast cancer live in low- or middle-income countries, where
access to affordable, timely, evidence-based treatment options for
breast cancer are often very limited. In higher-income countries,
ovarian function suppression (OFS) is now most often achieved by
so-called medical oophorectomy with gonadotrophin-releasing
agonists (GnRHas), and has become an established treatment
option for ER + breast cancer in premenopausal women most
often in combination with tamoxifen.4 In the SOFT and TEXT trials,
the combination of an aromatase inhibitor (AI) with OFS improved
the 5-year breast cancer-free interval more than OFS plus
tamoxifen, with the absolute difference in beneﬁt ranging widely
(1–15%) depending on the risk of recurrence.5 There was also a
5% beneﬁt of tamoxifen plus OFS vs. tamoxifen alone in higher-
risk patients. These trials have reinforced the application of OFS as
adjuvant treatment for ER + premenopausal disease.
While this adjuvant therapy is clearly effective, in order to
improve breast cancer outcomes associated with OvX, it is
important to better understand the biological effects that OvX
has in breast cancers, and to identify pre-treatment biomarkers
that could allow it to be targeted to patients with the greatest
potential to beneﬁt. While we,6–11 and others,12–16 have acquired
highly informative data relevant to patient management on the
molecular effects of endocrine therapy on breast cancer in
postmenopausal women, there is virtually no such information
on the biological effects of OFS or OvX in premenopausal women.
Here we report unique data on whole-genome expression
proﬁling of tumour biopsies before and after OvX in premeno-
pausal women with ER + breast cancer undergoing this treatment
for clinical management. We aimed to identify the most important
genes and pathways associated with the response to OvX as well
as determinants of that response. In addition, we aimed to assess
the degree to which the relationships differed from those
observed after an AI in postmenopausal women i.e. comparing
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withdrawal of oestrogen and progesterone vs. withdrawal of
oestrogen alone.
RESULTS
Patient demographics are described in Supplementary Table 1.
Ninety-three percent of patients were PgR + ve and thirty-eight
percent were HER2 + ve. This was an unexpectedly high level of
HER2 positivity, but was conﬁrmed by repeating the IHC and FISH
measurements for HER2; HER2 positivity correlated strongly with
high levels of ERBB2 gene expression. Plasma oestradiol (E2)
concentrations decreased from 406 ± 41 to 20.7 ± 2.6 pmol/l
(mean ± sem) 24 h after OvX and to 8.1 ± 0.8 pmol/l by mastect-
omy (2 weeks), with no further signiﬁcant decline at 4 weeks (6.6
± 0.9 pmol/l) (Fig. 1a). All patients had values below 80 pmol/L
after 24 h and below 30 pmol/L by 2 weeks after OvX.
Progesterone levels showed a similar pattern to E2 with all values
below 4 nmol/L by 2 weeks (and only one patient > 2nmol/L),
while mean LH and FSH levels increased markedly after OvX
(Fig. 1b–d). By 4 weeks all patients showed LH values > 18 IU/L,
and all but 4 patients showed FSH values > 20 IU/L.
Paired FFPE tumour samples before and 2 weeks after OvX
(time-points A or B and C, respectively) were available for 52 (A, B
& C; n = 35, A & C; n = 17) of the 56 patients. Of the 122 FFPE
samples, 18 were excluded from further analysis due to low
cellularity (see consort diagram, Supplementary Fig. S1.) Paired
frozen tumour samples were available for 53 (A, B & C; n = 42, A &
C; n = 3, B & C; n = 8) of the 56 patients. Of the 136 frozen samples,
31 were excluded from further analysis due to low cellularity, and
nine due to insufﬁcient RNA yield/quality. RNA from the remaining
88 paired frozen samples (32 patients total; 24 with A, B & C
samples; 5 with A & C and 3 with B & C) was arrayed on Illumina
whole genome expression BeadChips (see consort diagram,
Supplementary Figure 1). In cases where both A and B samples
were available, a mean of the two results was used as the pre-
treatment value for Ki67 (in FFPE samples) or gene expression.
Ki67 expression by IHC decreased from a median of 14.7%
(interquartile range; 8.8–24.6%) to 3.3% (0.8–11.4%) 2 weeks after
OvX equating to a median 77.5% (IQR 42.6–90.8%) reduction in
Ki67, but this varied greatly between patients (Fig. 2a). A reduction
in Ki67 was seen in 33/36 (91.7%) of tumours, with a reduction of
50% in 25/36 (69.4%). A total of 16/36 (44.4%) of tumours reached
complete cell cycle arrest17 (CCCA: Ki67≤ 2.7%). Baseline Ki67 was
similar in the HER2 -ve (median 15.0%; IQR 6.8–24.9%) and HER2 +
ve (13.2%; 8.8–24.4%) subgroups (Fig. 2b). The percentage fall in
Ki67 after OvX was not signiﬁcantly different (Mann–Whitney p-
value = 0.23) between the HER2 -ve (median 81.9%, IQR
50.3–91.5%, 16/21 > 50% reduction; 11/21 (52.3%) attaining CCCA)
and HER2 + ve subgroups (median 58.3%, IQR 19.4–85.7%, 9/15 >
50% reduction; 5/15 (33.3%) attaining CCCA). Of the three tumours
that did not show a fall in Ki67, two were HER2 + ve, one of which
showed a large rise in Ki67 (8.8 to 28%). There was a positive
correlation between baseline ER score and the percentage
decrease in Ki67 (Spearman rho = 0.38, p = 0.026).
Class comparison analysis identiﬁed a total of 1361 genes (530
up, 831 down) that were signiﬁcantly differentially expressed (FDR
< 1%) after OvX. Of these, 655 genes changed with an absolute
mean fold-change (FC) > 1.25 (257 up, 398 down; Supplementary
Figure 2). TFF1 was the most highly downregulated gene (FC =
0.20; p < 1e-7). Other archetypal oestrogen-regulated genes (e.g.
GREB1, PGR and PDZK1) also showed large decreases in
expression (Fig. 3, Table 1). Proliferation-associated genes e.g.
TOP2A, UBE2C and CDC20 were strongly downregulated (Fig. 3,
Table 1). Putative progesterone-regulated genes e.g. FKBP5, MYB
and SERPINA5 were also downregulated. Upregulated genes
showed less consistency in function with the largest changes
seen for many early-response genes (e.g. CYR61, DUSP1, FOSB and
FOS) (Table 1). Eleven of the top 20 upregulated genes, including
many of the early-response genes, were among the 31
upregulated genes that occurred in the POETIC presurgical 2-
week window trial in the absence of drug-treatment,18 indicating
that the change in expression of these genes is probably process-
related and not treatment-related. The gene expression changes
after OvX did not differ according to HER2 status, with no
differences apparent between the HER2 +ve and −ve subgroups.
One-way hierarchical clustering of the values representing the
change in expression of each of the 1361 signiﬁcantly differen-
tially expressed genes in Fig. 4a shows the degree of hetero-
geneity in the transcriptional response. Most tumours showed
Fig. 1 Changes in serum hormone concentrations of estradiol a progesterone b LH c and FSH d following OvX
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strong downregulation of archetypal oestrogen-regulated genes
(ERGs) and proliferation-associated genes (PAGs) (cluster 3). TFF1,
AURKA and UBE2C were the only three genes that were
downregulated in all cases. Clusters 1 and 2 comprised genes
that were less consistently downregulated and included many cell
cycle and DNA damage response pathway genes. The most highly
upregulated genes including many of the early-response genes
clustered very tightly in the small cluster 6 and showed consistent
upregulation in 75–97% of the samples. Other strongly upregu-
lated genes, including many immune-related genes (cytokines,
chemokines) grouped in cluster 4. Genes in cluster 5, which were
more variably upregulated, included collagens, cell surface
molecules and additional immune-related genes (Fig. 4a). There
were no clear patterns in the clustering according to HER2 status,
change in Ki67 or change in the AvERG (average expression of
PGR, GREB1, PGR and PDZK119). There was a weak correlation
between the changes in Ki67 and changes in AvERG (Spearman
rho = 0.43 p = 0.026).
Pathway analysis (IPA) of the 1361 signiﬁcantly differentially
expressed genes was performed to identify overrepresented
pathways (Fig. 4b). Twenty pathways were signiﬁcant at adjusted
p-values < 0.05, and the majority of these were proliferation-
related. Cyclin-dependent kinases (CDK1, 2 and 4) and cyclins
(CCNB1, CCND1 and CCNE1) were prominent in the majority of
these pathways; 43 genes occurred in at least two pathways
(Fig. 4c). Three pathways (‘Mitotic Roles of Polo-Like Kinase’,
‘Cyclins and Cell Cycle Regulation’ and ‘Oestrogen-mediated S-
phase Entry’) were signiﬁcantly inhibited, whilst ‘Cell Cycle: G1/S
Checkpoint Regulation’ was signiﬁcantly activated.
Higher baseline expression of ESR1 showed a weak statistically
insigniﬁcant correlation with degree of decrease in the Ki67
(Spearman rho = −0.28, p = 0.15; Supplementary Figure 2a), but
had stronger correlations with the degree of decrease in
proliferation genes after OvX e.g. TOP2A (rho = −0.45, p = 0.0096;
Supplementary Figure 3b), AURKA (rho = −0.36, p = 0.045) and
CDC20 (rho = −0.31, p = 0.082). Baseline ESR1 expression also
correlated with the change in AvERG (rho = −0.40, p = 0.025;
Supplementary Figure 3c) and ER H-score (Spearman r = 0.452; p =
0.030). In contrast, baseline ERBB2 showed no correlation with
change in Ki67, proliferation genes or AvERG after OvX.
We directly compared the gene expression changes observed
after OvX with those following neoadjuvant AI treatment in ER +
postmenopausal women with early breast cancer that we have
previously reported.9 We found that changes in the overall gene
expression after OvX strongly correlated (slope 0.55, Spearman
rho = 0.55, p < 1e-04; Supplementary Figure 4A) with those
reported after an AI.9 There were 432 genes (350 down, 82 up)
whose expression was signiﬁcantly affected by both OvX and AI
(FDR < 1%). Seventy-six of these genes were affected to a
signiﬁcantly greater degree (p < 0.05) by OvX (58 down, 18 up)
than AI, with an absolute FC 20% higher after OvX (geomean 1.44
vs. 1.20 for OvX and AI, respectively; p < 0.0001). Functional
annotation of these 76 genes by IPA identiﬁed PGR as the top
upstream regulator (p = 2.4e-07) with target molecules including
FOXO1, IL1R1, PTGES and SERPINA5. Just one gene, NR4A2, was
upregulated after OvX (FC 1.63) and downregulated after an AI (FC
0.77). No gene was affected more by AI than OvX. Five hundred
and ﬁfty-four genes (288 up, 266 down) signiﬁcantly changed after
OvX, but not after an AI. Pathway analysis of these genes revealed
over-representation of genes associated with proliferation (e.g.
CDK4, HDAC5 and SKP2) and immune response-related pathways
(e.g. ATM, NFKB1 and SOCS2).
OvX had a signiﬁcantly greater effect than AI on a proliferation
metagene20 (203/229 genes; 16.7% reduction vs. 12.4% reduction;
p = 0.039), but did not have a signiﬁcantly greater effect than an AI
on an ERG (oestrogen-regulated gene) metagene9 (31/34 genes;
32.2% reduction vs. 28.7%; p = 0.31).
We compiled a list of 245 putative progesterone-regulated
genes based on literature reports21–27 (and Mohammed21
personal communication) and 144 of these genes were present
in the ﬁnal ﬁltered data set (Supplementary Table 2). While
changes in the expression of these genes after OvX were strongly
correlated with the changes after AI in postmenopausal patients
(slope 0.50, rho = 0.69, p < 1e-04; Supplementary Figure 4B), OvX
had a greater effect than AI treatment both in terms of number of
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Fig. 3 Change in expression of selected genes in individual patients after OvX
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putative progesterone-regulated genes affected (50 vs. 41 with
FDR < 5%) and the absolute mean FC (1.41 vs. 1.28, p = 0.020).
DISCUSSION
The use of OFS, either medically using GnRHas or surgically by
OvX, as adjuvant treatment for ER + breast cancer in the
premenopausal setting is well established. However, in contrast
to studies of endocrine therapy in postmenopausal women, there
is very little information describing the effects of OFS on breast
tumour biology. In this study, we report unique data describing
the endocrine and genome-wide transcriptional effects of OvX in
premenopausal women with ER + breast cancer. Our objectives
were to identify the most important genes and pathways
Table 1. Top up and downregulated genes after OvX and comparison to AI treatment9
OvX AI9
Rank Gene All cases (n= 32) HER2 −ve (n= 22) All cases (n= 67)
Fold-change (post/pre) 95% CI Fold-change (post/pre) 95% CI Rank Fold-change (post/pre)
Downregulated genes
1 TFF1 0.20 0.15–0.27 0.21 0.14–0.31 1 0.34
2 UBE2C 0.38 0.31–0.47 0.38 0.30–0.49 2 0.42
3 SERPINA3 0.40 0.30–0.54 0.42 0.29–0.60 6 0.50
4 TOP2A 0.41 0.33–0.51 0.41 0.31–0.54 3 0.45
5 CDC20 0.43 0.34–0.54 0.43 0.33–0.55 7 0.51
6 NEK2 0.45 0.36–0.57 0.47 0.35–0.62 358 0.84
7 MSMB1 0.46 0.33–0.63 0.47 0.32–0.69 143 0.75
8 ASPM 0.47 0.39–0.56 0.46 0.37–0.59 17 0.56
9 SERPINA5 0.47 0.38–0.57 0.47 0.39–0.65 33 0.64
10 PRC1 0.47 0.40–0.55 0.46 0.36–0.57 12 0.53
11 NUSAP1 0.47 0.39–0.57 0.50 0.36–0.58 11 0.52
12 TFF3 0.48 0.37–0.62 0.47 0.33–0.64 129 0.75
13 PTTG1 0.48 0.40–0.58 0.48 0.37–0.59 26 0.63
14 TUBA3D 0.49 0.39–0.62 0.47 0.33–0.60 376 0.84
15 MAPT 0.49 0.42–0.57 0.45 0.40–0.56 452 0.85
16 NCAPG 0.50 0.43–0.59 0.50 0.42–0.60 25 0.62
17 KIAA0101 0.51 0.43–0.61 0.51 0.40–0.64 13 0.53
18 PDZK1 0.52 0.42–0.64 0.50 0.35–0.60 7 0.51
19 UHRF1 0.52 0.44–0.62 0.46 0.40–0.62 5 0.5
20 CELSR2 0.53 0.46–0.60 0.51 0.44–0.59 38 0.65
33 AURKA 0.56 0.49–0.64 0.58 0.49–0.68 24 0.61
38 BIRC5 0.57 0.50–0.65 0.58 0.50–0.67 889 0.93
52 E2F2 0.60 0.52–0.69 0.63 0.48–0.68 26 0.63
52 STC22 0.60 0.47–0.77 0.57 0.49–0.81 19 0.58
75 FKBP4 0.64 0.54–0.74 0.68 0.59–0.79 128 0.75
105 GREB1 0.67 0.61–0.75 0.68 0.58–0.79 44 0.66
125 MYB1 0.68 0.58–0.80 0.75 0.64–0.88 19 0.58
131 PGR 0.69 0.62–0.76 0.66 0.57–0.75 105 0.74
Upregulated genes
1 CYR61 3.47 2.63–4.58 3.13 2.22–4.40 – –
2 DUSP1 3.40 2.49–4.64 3.65 2.48–5.39 – –
3 FOSB2 2.60 1.59–4.23 2.66 1.39–5.09 – –
4 FOS1 2.45 1.65–3.65 2.59 1.55–4.34 – –
5 RGS1 2.38 1.87–3.04 2.50 1.90–3.28 – –
6 CTGF 2.24 1.83–2.74 2.15 1.75–2.65 – –
7 CPB12 2.21 1.46–3.35 2.62 1.61–4.25 – –
8 ZFP36 2.20 1.62–3.00 2.33 1.53–3.57 – –
9 EGR1 2.17 1.60–2.94 2.31 1.55–3.42 – –
10 ATF32 2.07 1.46–2.95 2.23 1.36–3.64 – –
Geometric mean fold-change values are shown, and the genes are ordered according to degree of change The top 20 genes downregulated by OvX plus
selected additional downregulated genes of interest and the top 10 upregulated genes are shown All genes shown have univariate P< 1 × 10−6 with exception
of 1P< 1 × 10−4 and 2P< 1 × 10−3
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CDK2 13 1 0 1 0 1 0 0 1 0 1 1 1 1 1 1 1 0 1 0 1
CDK4 10 1 0 1 1 0 0 0 1 0 1 0 1 1 1 1 0 0 1 0 0
CDK1 9 0 1 1 1 1 1 0 1 0 1 1 0 0 0 0 1 0 0 0 0
CCND1 9 0 0 1 1 0 0 0 1 0 1 0 1 1 1 1 0 0 1 0 0
CCNE1 9 0 0 1 0 0 0 0 1 0 1 1 1 1 1 0 0 0 1 0 1
BRCA1 8 0 1 1 1 1 0 0 0 1 0 1 0 0 0 1 1 0 0 0 0
CCNE2 8 0 0 1 0 0 0 0 1 0 1 1 1 1 1 0 0 0 0 0 1
CCNB1 7 0 1 1 1 0 1 0 1 0 0 1 0 0 0 0 1 0 0 0 0
CHEK1 7 0 1 0 1 1 0 0 0 1 0 0 1 0 0 1 1 0 0 0 0
E2F2 7 0 0 0 0 1 0 0 1 1 1 0 0 1 1 0 0 0 1 0 0
PCNA 6 1 0 1 0 1 0 1 0 0 0 0 0 0 0 1 0 1 0 0 0
CDC25A 6 0 0 0 0 1 1 0 1 0 1 0 0 0 1 0 1 0 0 0 0
TGFB3 6 0 0 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 1 1 1
CDC25C 5 0 1 0 1 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0
CCNB2 5 0 1 0 0 0 1 0 1 0 0 1 0 0 0 0 1 0 0 0 0
SFN 4 0 1 0 1 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0
PLK1 4 0 1 0 0 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0
GADD45G 4 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0
SLC19A1,RFC3-5 4 0 0 0 1 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0
IRS1,FGFR3,GAB1 4 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 0
PPM1J,PPP2R2C 4 0 0 0 0 1 1 0 1 0 0 0 0 1 0 0 0 0 0 0 0
CCNA2 4 0 0 0 0 0 0 0 1 0 1 0 1 0 0 0 0 0 0 0 1
JUN 4 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 0 0 1 0
SMAD3 4 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1
KAT2B 3 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0
MSH6 3 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0
HDAC11 3 0 0 0 1 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0
FANCD2,BLM 3 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0
SMARCA2 & B1 3 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0
PA2G4,CDKN2B 3 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 1 0 0
NFKB1 3 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 0
TOP2A 2 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
MCM7 2 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
LIG1 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
PKMYT1 2 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
PRKDC 2 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
BARD1,FANCG 2 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
POLR2H,POLR2L 2 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
FEN1 2 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0
RBBP8 2 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0
NCOA3,FOS 2 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0
BIRC5 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0
PTGS2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0
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associated with the response to OvX as well as determinants of
that response and to evaluate the extent to which these differed
from those observed after an AI in postmenopausal women. We
found that after OvX, tumour cell proliferation was reduced in
almost all patients and there were large decreases in ERGs,
proliferation-associated genes and putative progesterone-
regulated genes. The changes after OvX did not differ according
to HER2 status and correlated strongly with those seen after AI
treatment in postmenopausal women,9 but were of a greater
magnitude. Moreover, OvX appeared to have more of an effect on
progesterone-regulated genes than AI.
This pre-operative study provided a unique opportunity to
investigate the endocrine and molecular effects of OvX in ER +
premenopausal breast cancer and, to our knowledge, presents the
only data describing the molecular effects of OvX on breast
tumour biology. It should be noted that the large variation in
hormone levels in premenopausal women that occurs through the
menstrual cycle would lead to widely differing hormonal milieu at
the time of OvX in this study. This could impact on the baseline
molecular proﬁles since it has been shown that there are
signiﬁcant differences in the expression of ERGs and
proliferation-associated genes through the menstrual cycle.28,29
In order to reduce the effect of such changes, we used the average
Ki67 or gene expression value of two pre-treatment tumour
samples taken 2 weeks apart as the baseline measurement in the
majority of patients.
As expected, plasma hormone levels of E2 rapidly fell to reach
postmenopausal levels 2 weeks after OvX due to removal of
ovarian hormonal synthesis, with residual E2 now synthesised via
aromatase in peripheral tissues as in postmenopausal women.
Tumour cell proliferation measured by Ki67 showed large
variability, and was similar to that seen after an AI in
postmenopausal ER + ve breast cancer,6,9 with a reduction in the
vast majority of tumours.
There is some evidence that HER2 + ve tumours do not respond as
well as HER2 –ve tumours to AI therapy.30 In this Vietnamese ER + ve
population there was a higher than expected level of HER2
positivity which was conﬁrmed by gene expression measure-
ments; although it is possible that this is due to ethnic origin it
may also be due to chance. In contrast to previous reports30 we
did not observe a higher baseline Ki67 in the HER2 + ve compared
to the HER2 -ve patients, again this may be due to ethnic origin
but it may also be due to chance. Whilst the reduction in Ki67 was
nearly 1.5-fold greater in the HER2 –ve group compared to the
HER2 + ve, this did not reach signiﬁcance due to the large
variability in Ki67 response and low numbers, such that the study
had only 50% power to detect such a change as signiﬁcant.
Similarly, the gene expression changes after OvX did not differ
according to HER2 status nor were there clear patterns in the
clustering of the gene expression data according to HER2 status.
Overall, our data suggest that HER2 positivity may not be a major
determinant of response to OvX; this merits study in available
large clinical trial cohorts.
The changes in gene expression after OvX mirrored those
previously reported after an AI in postmenopausal ER + ve breast
cancer9 and displayed strong downregulation of ERGs and PAGs
and upregulation of immune-related genes and collagens with a
high degree of heterogeneity. The most highly upregulated genes
(e.g. CYR61, DUSP1, FOSB and FOS), which increased in almost all
tumours, were early-response genes. However, the upregulation of
these genes may be process- rather than treatment-related, as a
very similar group of genes were upregulated in a study of the
heterogeneity of gene expression in the absence of drug-
treatment and this was attributed to ischaemia after surgery
rather than any treatment effect.18
Direct comparison of the effects after OvX and AI therapy
showed that whilst changes in overall gene expression were
strongly correlated, the changes after OvX were of a greater
magnitude. This could be because, in addition to suppressing E2
levels, OvX also suppresses progesterone levels, which does not
occur after AI. This also leads to the hypothesis that OvX may
affect progesterone-regulated genes to a greater extent than AI.
Indeed, we found some evidence for this with PGR being the most
highly signiﬁcant upstream regulator of the genes affected more
by OvX than AI; but overall, the differences between the two
treatments were not large. This may reﬂect the fact that after an
AI, the progesterone receptor gene (PGR) itself is downregulated,
which would reduce progesterone signalling and receptor-
mediated effects indirectly, despite progesterone levels (like E2
levels) being much lower in postmenopausal women.
OFS is now most often achieved by so-called medical
oophorectomy with GnRHas. The changes seen in premenopausal
ER + breast cancer in the current study using OvX to accomplish
OFS would be expected to be similar to those seen after use of
GnRHa alone after their initial stimulatory phase. However, over
the ﬁrst few months, ovarian oestrogen synthesis often shows
partial recovery after a GnRHa as a result of a recovery of FSH
levels.31 Thus, molecular changes with GnRHas may be of a lower
magnitude than with OvX. It should be noted that the addition of
an AI to GnRHa does not uniformly suppress the residual ovarian
synthesis, and in some cases may lead to increased synthesis.32,33
In conclusion, we report for the ﬁrst time the most important
genes and pathways associated with the response to OvX. The
degree of change in gene expression varied between patients and
may reﬂect the degree of beneﬁt derived from OvX, but this would
need to be conﬁrmed in much larger studies. The changes after
OvX were largely similar, but of a greater magnitude to those after
AI in postmenopausal patients; however, OvX appeared to have a
greater effect on progesterone-regulated genes than AI.
Mastectomy
Time
T=0 T=2 weeks
Diagnosis OvX
Blood 
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T=24h
Procedure
2 weeks 2 weeks
Post-
mastectomy
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Fig. 5 Study design and sampling schedule
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METHODS
Patients and study design
A single-arm study of neoadjuvant OvX was conducted in 56 premeno-
pausal women with ER + breast cancer in Vietnam. The primary objective
of the study was to determine whether the variation in gene expression in
different phases of the menstrual cycle could predict for change in Ki67
following oophorectomy. Thus, Ki67 was the primary end-point of the
study, although the work reported here was on the conduct of a secondary
objective. The study was planned to recruit 70 patients, but was curtailed
at 56 because of recruitment difﬁculties.
The study design and sampling schedule are shown in Fig. 5.
Premenopausal women with operable, palpable stage IIa-IIIb ER + invasive
breast cancer for whom modiﬁed radical mastectomy and surgical bilateral
salpingo-oophorectomy was planned as part of their breast cancer
treatment were eligible.
Patients had to report regular menstrual cycles (≥three) of 25–35 days and
must not have received any prior chemotherapy or radiotherapy for their
cancer. Exclusion criteria included: metastatic disease, pregnancy, lactation
within last 3 months, use of oral contraceptives or other hormonal
contraceptives and concomitant use of medications known to inﬂuence
oestrogen levels.
The study was approved by the Institutional Ethics Committee of the
National Cancer Hospital, Hanoi, Vietnam, from where all study participants
were recruited and by the Research Ethics Board of the University of
Toronto, Canada, from where the study was coordinated. The Committee
for Clinical Research at the Royal Marsden Hospital, London further
approved the analysis of the samples collected in this trial. All participants
provided written informed consent.
Blood samples were taken pre-OvX (on day of OvX prior to anaesthesia
or pre-operative medication), 24 h post-OvX, 2 weeks post-OvX (pre-
operative mastectomy) and 4 weeks post-OvX (Fig. 1). Breast tumour core
biopsies were taken at three time-points; diagnosis (A), intra-operative at
OvX (B; 2 weeks) and during mastectomy (C; 4 weeks). At each time-point
one core biopsy was snap-frozen in liquid nitrogen for RNA extraction and
another ﬁxed in neutral buffered formalin and parafﬁn embedded for
immunohistochemistry.
Serum hormone measurements
Serum concentrations of E2 were measured by radioimmunoassay
following pre-assay puriﬁcation using an organic extraction as described
previously.34,35 Progesterone was measured using a solid-phase radio-
immunoassay (Beckman Coulter IM1188). LH and FSH were measured
using immunoradiometric assays (IBL International MG12151 and Dia-
source KIP0841 respectively).
Immunohistochemistry
Hematoxylin and eosin sections were prepared for all FFPE and frozen
tumour samples, and were reviewed to conﬁrm diagnosis and assess
tumour content. Samples with tumour content < 40% were excluded from
further analysis. Immunohistochemistry (IHC) and scoring for ER, PgR and
Ki67 were performed as reported previously.7,36 HER-2 was measured
immunohistochemically using the HercepTest (DakoCytomation) and by
ﬂuorescent in situ hybridisation (Vysis Pathvysion, Downers Grove, IL)
according to manufacturer’s instructions. HER-2 was considered positive if
immunohistochemical staining was scored 3 +, or 2 + if the ﬂuorescence
in situ hybridisation analysis indicated an ampliﬁcation ratio of >2.0.
Measurement of gene expression
Total RNA was extracted from frozen tissue using the RNeasy Mini kit
(Qiagen, Sussex, UK). RNA quality was checked using an Agilent Bioanalyser
(Santa Clara, CA, USA). Samples were excluded from further analysis if RNA
quality was inadequate (RNA integrity values (RIN) of < 4.0). RNA
ampliﬁcation, labelling and hybridisation on HumanHT-12_v4 Expression
BeadChips (Illumina, San Diego, CA, USA) were performed according to the
manufacturer’s instructions. Raw data were extracted using GenomeStudio
software, ﬁltered to remove any non-expressed probes (detection p-value
> 0.01) and transformed and normalised using variance-stabilising
transformation and the robust spline normalisation method included in
the lumi R package (http://www.bioconductor.org). Probes were further
removed if they were not detected (p > 0.01) in > = 25% of samples
resulting in 42.7% (20,216/47,323) of the starting probes remaining for the
downstream data analysis.
To compare the gene expression changes observed after OvX in the
current study with those following AI treatment, we used Illumina data (on
HumanWG6_v2 Expression BeadChips) from our previously published
neoadjuvant study of the effects of 2 weeks’ anastrozole monotherapy in
112 ER + postmenopausal women with early breast cancer.9 The individual
Illumina data sets from the two studies were merged using nuID’s created
from the Illumina probe sequences, yielding 29563 common probes. The
combined data set was pre-processed as described above and the data
were then batch corrected using the ComBat function in the sva R package
(http://www.bioconductor.org). Probes were ﬁltered out if they were not
detected (p > 0.01) in > = 25% of samples resulting in 12716 of the probes
remaining for the downstream data analysis.
Data analysis and statistical methods
When multiple probes were mapped to the same gene, the most variable
probe measured by interquartile range IQR across samples was selected to
represent the gene. Multivariate permutation tests were used to identify
differentially expressed genes between the paired samples. FDR values
were calculated to allow for 80% probability that genes attained the set
FDR threshold. The signiﬁcantly differentially expressed genes were
subjected to Ingenuity Pathway Analysis (IPA). The pathways were
considered as signiﬁcantly altered if the adjusted p < 0.05 after using
Benjamini–Hochberg Multiple Testing Correction. Wilcoxon matched-pairs
signed rank test was used to evaluate the signiﬁcance of the percentage
change of expression between pairs of samples. Power calculations
indicated that there would be at least 85% power to detect correlations of
greater than 0.6 between changes in gene expression and Ki67. The
Mann–Whitney test was used to test for signiﬁcance of any differences in
the expression of genes after OvX compared to an AI. Wilcoxon matched-
pairs signed rank test was used to evaluate the signiﬁcance of differences
in the absolute fold-change of individual genes after OvX compared to an
AI. GraphPad Prism 6 (Graphpad Software Inc.) was used for some of the
statistical analyses in this study. The reported p-values are two-tailed, with
p < 0.05 considered as signiﬁcant.
Data availability
Gene expression data from this study is deposited at GEO with accession
number GSE97221.
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